Hussein Yassine, MD, Keck School of Medicine, University of Southern California, Los Angeles, CA, discusses the importance of a personalized approach to dementia treatment and prevention, as opposed to population-wide approaches. For example, a recent trial whereby supplemental docosahexaenoic acid (DHA) was given to cognitively normal patients with AD genetic risk factors found that the increase of omega-3s in the brains of patients with the APOE4 gene was significantly lower than without it. This suggests that the APOE4 system consumes more omega-3s than APOE2 or APOE3, or that it is not absorbed as efficiently. Given this heterogeneity, Dr Yassine proposes that it is important to assess risk on an individual basis in order to then provide personalized interventions to those patients. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
